CD19 and B-cell non-Hodgkin lymphoma: Thus, MYC, BCL2, and BCL6 overexpression and chromosomal rearrangements in aggressive B-cell lymphomas correlate with unfavorable prognosis after CD19-CAR T cell therapy.